Cell chemical biologyBioengineeringPeer-reviewed journal article
De novo design of Ras isoform selective binders
Jason Z. ZhangiD, Xinting LiiD, Alexa Rane Batingana, Caixuan Liu, Hanlun JiangiD, Kevin ShannoniD, Benjamin J. HuangiD, Kejia WuiD, David A. BakeriD
Abstract
The proto-oncogene Ras which governs diverse intracellular pathways has four major isoforms (KRAS4A, KRAS4B, HRAS, and NRAS) with substantial sequence homology and similar in vitro biochemistry. There is considerable interest in investigating the roles of these independently as their association with different cancers vary, but there are few Ras isoform-specific binding reagents as the only significant sequence differences are in their disordered and highly charged C-termini which have been difficult to elicit antibodies against. To overcome this limitation, we use deep learning-based methods to de novo design Ras isoform-specific binders (RIBs) for all major Ras isoforms that specifically target the Ras C-terminus. The RIBs bind to their target Ras isoforms both in vitro and in cells with remarkable specificity, disrupting their membrane localization and inhibiting Ras activity, and should contribute to dissecting the distinct roles of Ras isoforms in biology and disease.
- Citations
- 14
- FWCI
- 10.34
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Steric shielding of the KRAS4B hypervariable region enables isoform-specific inhibition of prenylation
Jonas N. Maskos, Yvonne Stark, … Andreas Plückthun·bioRxiv·Mar 20, 2026
- Mirror-image mRNA display uncovers isoform-selective D-peptide macrocycles targeting a cryptic KRAS pocket
Matthew J. Mitcheltree, Nicole Boo, … Kaustav Biswas·bioRxiv·May 22, 2026
- Divergent CRD-Dependent Mechanisms Govern RAS Isoform-Selective Recruitment of CRAF and ARAF
Shrhea Banerjee, Sravani Malasani, … Zhihong Wang·Protein SciencePeer-reviewed·Jul 9, 2026
- RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.
Katarzyna Z. Haza, Heather L. Martin, … Darren Charles Tomlinson·Nature CommunicationsPeer-reviewed·Jun 30, 2021
- bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights
S. Lim, R. Khoo, … A. W. Partridge·bioRxiv·Jun 26, 2020
- Engineering protein-specific proteases: targeting active RAS
Y. Chen, E. A. Toth, … P. N. Bryan·bioRxiv·Sep 21, 2020